Trial Profile
A multicenter phase I/II dose excalation study of lenalidomide in relapse/refractory Waldenstrom macroglobulinemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 03 Jul 2016 Status changed from active, no longer recruiting to completed.
- 26 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 12 Jul 2011 New trial record